First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report

BACKGROUND: The acquired resistance to ALK tyrosine kinase inhibitors (TKIs) in ALK-rearranged NSCLC is associated with poor survival outcomes and poses distinct clinical challenges. It is essential to develop potential therapeutic strategies for overcoming resistance. CASE PRESENTATION: Here, we fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shuang, Feng, Weineng, Deng, Yanming, Liang, Jianmiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979531/
https://www.ncbi.nlm.nih.gov/pubmed/36864442
http://dx.doi.org/10.1186/s12957-023-02935-9
_version_ 1784899744956416000
author Yang, Shuang
Feng, Weineng
Deng, Yanming
Liang, Jianmiao
author_facet Yang, Shuang
Feng, Weineng
Deng, Yanming
Liang, Jianmiao
author_sort Yang, Shuang
collection PubMed
description BACKGROUND: The acquired resistance to ALK tyrosine kinase inhibitors (TKIs) in ALK-rearranged NSCLC is associated with poor survival outcomes and poses distinct clinical challenges. It is essential to develop potential therapeutic strategies for overcoming resistance. CASE PRESENTATION: Here, we first report a female lung adenocarcinoma patient with an acquired ALK resistance mutation (ALK 11171N) who was treated with ensartinib. Her symptoms significantly improved after only 20 days, and with a side effect of mild rash. Follow-up images observed no further brain metastases after 3 months. CONCLUSIONS: This treatment may provide a new therapeutic strategy for ALK TKIs resistant patients, especially in position 1171 of ALK exon20.
format Online
Article
Text
id pubmed-9979531
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99795312023-03-03 First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report Yang, Shuang Feng, Weineng Deng, Yanming Liang, Jianmiao World J Surg Oncol Case Report BACKGROUND: The acquired resistance to ALK tyrosine kinase inhibitors (TKIs) in ALK-rearranged NSCLC is associated with poor survival outcomes and poses distinct clinical challenges. It is essential to develop potential therapeutic strategies for overcoming resistance. CASE PRESENTATION: Here, we first report a female lung adenocarcinoma patient with an acquired ALK resistance mutation (ALK 11171N) who was treated with ensartinib. Her symptoms significantly improved after only 20 days, and with a side effect of mild rash. Follow-up images observed no further brain metastases after 3 months. CONCLUSIONS: This treatment may provide a new therapeutic strategy for ALK TKIs resistant patients, especially in position 1171 of ALK exon20. BioMed Central 2023-03-02 /pmc/articles/PMC9979531/ /pubmed/36864442 http://dx.doi.org/10.1186/s12957-023-02935-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Yang, Shuang
Feng, Weineng
Deng, Yanming
Liang, Jianmiao
First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report
title First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report
title_full First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report
title_fullStr First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report
title_full_unstemmed First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report
title_short First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report
title_sort first case report of ensartinib in a patient with metastatic alk rearranged lung cancer with alk i1171n mutation: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979531/
https://www.ncbi.nlm.nih.gov/pubmed/36864442
http://dx.doi.org/10.1186/s12957-023-02935-9
work_keys_str_mv AT yangshuang firstcasereportofensartinibinapatientwithmetastaticalkrearrangedlungcancerwithalki1171nmutationacasereport
AT fengweineng firstcasereportofensartinibinapatientwithmetastaticalkrearrangedlungcancerwithalki1171nmutationacasereport
AT dengyanming firstcasereportofensartinibinapatientwithmetastaticalkrearrangedlungcancerwithalki1171nmutationacasereport
AT liangjianmiao firstcasereportofensartinibinapatientwithmetastaticalkrearrangedlungcancerwithalki1171nmutationacasereport

Ejemplares similares